Dyne Therapeutics reports additional one-year Phase 1/2 ACHIEVE data
Dyne Therapeutics announced additional one-year clinical data from its Phase 1/2 ACHIEVE trial of z-basivarsen (DYNE-101) for myotonic dystrophy type 1 (DM1).
Dyne Therapeutics announced additional one-year clinical data from its Phase 1/2 ACHIEVE trial of z-basivarsen (DYNE-101) for myotonic dystrophy type 1 (DM1).